Ionis Pharmaceuticals (IONS) Operating Expenses (2009 - 2026)

Ionis Pharmaceuticals' Operating Expenses history runs 18 years deep, the most recent figure standing at $363.5 million for Q1 2026.

• On a quarterly basis, Operating Expenses rose 30.54% year-over-year to $363.5 million in Q1 2026; TTM through Mar 2026 was $1.4 billion, a 18.56% increase from a year earlier, with the FY2025 full-year figure at $1.3 billion, up 12.3% from the prior year.
• Operating Expenses eased to $363.5 million in Q1 2026 per IONS's latest filing, from $417.8 million in the prior quarter.
• Across five years, Operating Expenses topped out at $417.8 million in Q4 2025 and bottomed at $199.4 million in Q1 2022.
• The 5-year median for Operating Expenses is $287.5 million (2023), against an average of $294.6 million.
• Across the five-year window, Operating Expenses soared 64.04% in 2022 and slipped 8.14% in 2023, its largest moves.
• Year by year, Operating Expenses stood at $359.9 million in 2022, then fell by 8.14% to $330.6 million in 2023, then advanced by 2.05% to $337.4 million in 2024, then advanced by 23.83% to $417.8 million in 2025, then declined by 12.99% to $363.5 million in 2026.
• Per Business Quant, the three latest IONS Operating Expenses figures stand at $363.5 million (Q1 2026), $417.8 million (Q4 2025), and $316.9 million (Q3 2025).